BURLINGTON, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that
it will report its third-quarter 2018 financial results after the close of the U.S. financial markets on Wednesday,
November 7, 2018. Flexion’s management will host a conference call at 4:30 p.m. ET to discuss the results and provide an update on
business operations.
The dial-in number for the conference call is 1-855-770-0022 for domestic participants and 1-908-982-4677 for international
participants, with Conference ID #4655468. A live webcast of the conference call can also be accessed through the "Investors" tab on the Flexion Therapeutics website. A webcast replay will be available online
after the call.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local
therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative
arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. For the past two years, Flexion has been
named one of the Best Places to Work by the Boston Business Journal, and Flexion was also recognized as a Top Place to
Work in Massachusetts by The Boston Globe in 2017.
Contact:
Scott Young
Vice President, Corporate Communications and Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
syoung@flexiontherapeutics.com
